
Gensight Biologics SA
PAR:SIGHT

Intrinsic Value
The intrinsic value of one
SIGHT
stock under the Base Case scenario is
0.238
EUR.
Compared to the current market price of 0.244 EUR,
Gensight Biologics SA
is
Overvalued by 2%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Gensight Biologics SA
Fundamental Analysis


Revenue & Expenses Breakdown
Gensight Biologics SA
Balance Sheet Decomposition
Gensight Biologics SA
Current Assets | 13m |
Cash & Short-Term Investments | 6.9m |
Receivables | 1.3m |
Other Current Assets | 4.7m |
Non-Current Assets | 2m |
Long-Term Investments | 519k |
PP&E | 1.4m |
Intangibles | 66k |
Free Cash Flow Analysis
Gensight Biologics SA
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
Gensight Biologics SA
Revenue
|
2.4m
EUR
|
Operating Expenses
|
-39.5m
EUR
|
Operating Income
|
-37.1m
EUR
|
Other Expenses
|
5m
EUR
|
Net Income
|
-32.1m
EUR
|
SIGHT Profitability Score
Profitability Due Diligence
Gensight Biologics SA's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Score
Gensight Biologics SA's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
SIGHT Solvency Score
Solvency Due Diligence
Gensight Biologics SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.

Score
Gensight Biologics SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SIGHT Price Targets Summary
Gensight Biologics SA
According to Wall Street analysts, the average 1-year price target for
SIGHT
is 0.388 EUR
with a low forecast of 0.364 EUR and a high forecast of 0.42 EUR.
Dividends
Current shareholder yield for SIGHT is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
SIGHT
stock under the Base Case scenario is
0.238
EUR.
Compared to the current market price of 0.244 EUR,
Gensight Biologics SA
is
Overvalued by 2%.